Just ahead of Alvotech publishing its annual results, the biosimilars developer has revealed a first filing for its AVT23 proposed biosimilar to Xolair (omalizumab). In conjunction with partner Advanz Pharma, the firm has received confirmation from the UK Medicines and Healthcare Products Regulatory Agency that the omalizumab candidate has been accepted for review by the MHRA.
With Alvotech citing global sales of Xolair that came to around $4.4bn in 2024, omalizumab is a significant target for the biosimilars developer. And under the deal struck between Alvotech and Advanz